Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Secondary cement injection technique reduces pulmonary embolism in total hip arthroplasty.

Schmidutz F, Düll T, Voges O, Grupp T, Müller P, Jansson V.

Int Orthop. 2012 Aug;36(8):1575-81. doi: 10.1007/s00264-012-1537-2. Epub 2012 Apr 15.

2.

Long-term results of 58 hip cup revision arthroplasties using a threaded ring implant.

von Schulze Pellengahr C, Düll T, Müller PE, Dürr HR, Baur-Melnyk A, Maier M, Birkenmaier C, Jansson V.

Arch Orthop Trauma Surg. 2007 Jan;127(1):71-4. Epub 2006 Sep 14.

PMID:
16972059
3.

A positron-emitting internal marker for identification of normal tissue by positron emission tomography: phantom studies and validation in patients.

Thomas CT, Meyer CR, Koeppe RA, Kalemkerian GP, Fisher SJ, Dull TL, Zasadny KR, Wahl RL.

Mol Imaging Biol. 2003 Mar-Apr;5(2):79-85.

PMID:
14499148
4.
5.

Production of human clotting Factor IX without toxicity in mice after vascular delivery of a lentiviral vector.

Tsui LV, Kelly M, Zayek N, Rojas V, Ho K, Ge Y, Moskalenko M, Mondesire J, Davis J, Roey MV, Dull T, McArthur JG.

Nat Biotechnol. 2002 Jan;20(1):53-7.

PMID:
11753362
6.

A new-generation stable inducible packaging cell line for lentiviral vectors.

Farson D, Witt R, McGuinness R, Dull T, Kelly M, Song J, Radeke R, Bukovsky A, Consiglio A, Naldini L.

Hum Gene Ther. 2001 May 20;12(8):981-97.

PMID:
11387062
7.

Large-scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols.

Farson D, McGuinness R, Dull T, Limoli K, Lazar R, Jalali S, Reddy S, Pennathur-Das R, Broad D, Finer M.

J Gene Med. 1999 May-Jun;1(3):195-209.

PMID:
10738568
8.

Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery.

Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, Naldini L, Trono D.

J Virol. 1998 Dec;72(12):9873-80.

9.

A third-generation lentivirus vector with a conditional packaging system.

Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L.

J Virol. 1998 Nov;72(11):8463-71.

10.

Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains.

Roberts MR, Cooke KS, Tran AC, Smith KA, Lin WY, Wang M, Dull TJ, Farson D, Zsebo KM, Finer MH.

J Immunol. 1998 Jul 1;161(1):375-84.

11.

Mosaicicm in bcr-abl protein expression in B cells in chronic myelogenous leukemia.

Weissinger EM, Thalmeier K, Dull T, Grammer C, Kempkes B, Brielmeier M, Schumm M, Kolb HJ.

Int J Cancer. 1996 Nov 27;68(5):577-82.

12.

Late pulmonary impairment following allogeneic bone marrow transplantation.

Beinert T, Düll T, Wolf K, Holler E, Vogelmeier C, Behr J, Kolb H.

Eur J Med Res. 1996 Apr 18;1(7):343-8.

PMID:
9364037
13.

Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors.

Roberts MR, Qin L, Zhang D, Smith DH, Tran AC, Dull TJ, Groopman JE, Capon DJ, Byrn RA, Finer MH.

Blood. 1994 Nov 1;84(9):2878-89.

14.

[Erroneous interpretation of Y-chromosome deletion del (Y)(q11) with infertility as Philadelphia chromosome positive chronic myeloid leukemia].

Mittermüller J, Düll T, Schmetzer H.

Med Klin (Munich). 1994 May 15;89(5):279-82. German. No abstract available.

PMID:
8052184
15.

kat: a high-efficiency retroviral transduction system for primary human T lymphocytes.

Finer MH, Dull TJ, Qin L, Farson D, Roberts MR.

Blood. 1994 Jan 1;83(1):43-50.

16.

Insulin-EGF receptor chimerae mediate tyrosine transphosphorylation and serine/threonine phosphorylation of kinase-deficient EGF receptors.

Tartare S, Ballotti R, Lammers R, Alengrin F, Dull T, Schlessinger J, Ullrich A, Van Obberghen E.

J Biol Chem. 1991 May 25;266(15):9900-6.

17.

Late effects in bone marrow transplanted patients--a multicenter study supported by EBMT and EULEP.

Weinsheimer W, Kolb HJ, Düll T, Fliedner TM.

Bone Marrow Transplant. 1991;8 Suppl 1:25. No abstract available.

PMID:
1760630
18.

Molecular cloning of cDNAs encoding bovine and human lactoperoxidase.

Dull TJ, Uyeda C, Strosberg AD, Nedwin G, Seilhamer JJ.

DNA Cell Biol. 1990 Sep;9(7):499-509.

PMID:
2222811
19.

Functionally distinct insulin receptors generated by tissue-specific alternative splicing.

Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A, McClain DA.

EMBO J. 1990 Aug;9(8):2409-13.

20.

Epidermal growth factor receptor cytoplasmic domain mutations trigger ligand-independent transformation.

Massoglia S, Gray A, Dull TJ, Munemitsu S, Kun HJ, Schlessinger J, Ullrich A.

Mol Cell Biol. 1990 Jun;10(6):3048-55.

21.

Characterization of an insulin receptor mutant lacking the subunit processing site.

Williams JF, McClain DA, Dull TJ, Ullrich A, Olefsky JM.

J Biol Chem. 1990 May 25;265(15):8463-9.

22.

Intermolecular transphosphorylation between insulin receptors and EGF-insulin receptor chimerae.

Ballotti R, Lammers R, Scimeca JC, Dull T, Schlessinger J, Ullrich A, Van Obberghen E.

EMBO J. 1989 Nov;8(11):3303-9.

24.

HER2 cytoplasmic domain generates normal mitogenic and transforming signals in a chimeric receptor.

Lee J, Dull TJ, Lax I, Schlessinger J, Ullrich A.

EMBO J. 1989 Jan;8(1):167-73.

25.

Truncation of the human EGF receptor leads to differential transforming potentials in primary avian fibroblasts and erythroblasts.

Khazaie K, Dull TJ, Graf T, Schlessinger J, Ullrich A, Beug H, Vennström B.

EMBO J. 1988 Oct;7(10):3061-71.

26.

Biological activities of EGF-receptor mutants with individually altered autophosphorylation sites.

Honegger A, Dull TJ, Bellot F, Van Obberghen E, Szapary D, Schmidt A, Ullrich A, Schlessinger J.

EMBO J. 1988 Oct;7(10):3045-52.

27.

Kinetic parameters of the protein tyrosine kinase activity of EGF-receptor mutants with individually altered autophosphorylation sites.

Honegger A, Dull TJ, Szapary D, Komoriya A, Kris R, Ullrich A, Schlessinger J.

EMBO J. 1988 Oct;7(10):3053-60.

28.

Mutation of the insulin receptor at tyrosine 960 inhibits signal transmission but does not affect its tyrosine kinase activity.

White MF, Livingston JN, Backer JM, Lauris V, Dull TJ, Ullrich A, Kahn CR.

Cell. 1988 Aug 26;54(5):641-9.

PMID:
2842060
29.

Properties of a human insulin receptor with a COOH-terminal truncation. II. Truncated receptors have normal kinase activity but are defective in signaling metabolic effects.

Maegawa H, McClain DA, Freidenberg G, Olefsky JM, Napier M, Lipari T, Dull TJ, Lee J, Ullrich A.

J Biol Chem. 1988 Jun 25;263(18):8912-7.

30.

Properties of a human insulin receptor with a COOH-terminal truncation. I. Insulin binding, autophosphorylation, and endocytosis.

McClain DA, Maegawa H, Levy J, Huecksteadt T, Dull TJ, Lee J, Ullrich A, Olefsky JM.

J Biol Chem. 1988 Jun 25;263(18):8904-11.

31.

Release of a phorbol ester-induced mitogenic block by mutation at Thr-654 of the epidermal growth factor receptor.

Livneh E, Dull TJ, Berent E, Prywes R, Ullrich A, Schlessinger J.

Mol Cell Biol. 1988 Jun;8(6):2302-8.

32.

A mutant epidermal growth factor receptor with defective protein tyrosine kinase is unable to stimulate proto-oncogene expression and DNA synthesis.

Honegger AM, Szapary D, Schmidt A, Lyall R, Van Obberghen E, Dull TJ, Ullrich A, Schlessinger J.

Mol Cell Biol. 1987 Dec;7(12):4568-71.

33.

Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.

Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A.

EMBO J. 1987 Nov;6(11):3341-51.

34.

A mutant insulin receptor with defective tyrosine kinase displays no biologic activity and does not undergo endocytosis.

McClain DA, Maegawa H, Lee J, Dull TJ, Ulrich A, Olefsky JM.

J Biol Chem. 1987 Oct 25;262(30):14663-71.

35.

Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing.

Honegger AM, Dull TJ, Felder S, Van Obberghen E, Bellot F, Szapary D, Schmidt A, Ullrich A, Schlessinger J.

Cell. 1987 Oct 23;51(2):199-209.

PMID:
3499230
36.

Tissue-specific and developmentally regulated transcription of the insulin-like growth factor 2 gene.

Gray A, Tam AW, Dull TJ, Hayflick J, Pintar J, Cavenee WK, Koufos A, Ullrich A.

DNA. 1987 Aug;6(4):283-95.

PMID:
3652904
37.

Characterization of an endogenous substrate of the insulin receptor in cultured cells.

White MF, Stegmann EW, Dull TJ, Ullrich A, Kahn CR.

J Biol Chem. 1987 Jul 15;262(20):9769-77.

38.

Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin.

Chou CK, Dull TJ, Russell DS, Gherzi R, Lebwohl D, Ullrich A, Rosen OM.

J Biol Chem. 1987 Feb 5;262(4):1842-7.

39.

Transforming potential of the c-fms proto-oncogene (CSF-1 receptor).

Roussel MF, Dull TJ, Rettenmier CW, Ralph P, Ullrich A, Sherr CJ.

Nature. 1987 Feb 5-11;325(6104):549-52.

PMID:
3027579
40.

A chimaeric receptor allows insulin to stimulate tyrosine kinase activity of epidermal growth factor receptor.

Riedel H, Dull TJ, Schlessinger J, Ullrich A.

Nature. 1986 Nov 6-12;324(6092):68-70.

PMID:
3024008
41.

Protein kinases in cellular signal transduction: tyrosine kinase growth factor receptors and protein kinase C.

Ullrich A, Riedel H, Yarden Y, Coussens L, Gray A, Dull T, Schlessinger J, Waterfield MD, Parker PJ.

Cold Spring Harb Symp Quant Biol. 1986;51 Pt 2:713-24. No abstract available.

PMID:
3472757
42.

Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes.

Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, Coussens L, Liao YC, Tsubokawa M, et al.

Nature. 1985 Feb 28-Mar 6;313(6005):756-61.

PMID:
2983222
43.

Insulin-like growth factor II precursor gene organization in relation to insulin gene family.

Dull TJ, Gray A, Hayflick JS, Ullrich A.

Nature. 1984 Aug 30-Sep 5;310(5980):777-81.

PMID:
6382022
44.

Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells.

Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Libermann TA, Schlessinger J, et al.

Nature. 1984 May 31-Jun 6;309(5967):418-25.

PMID:
6328312
45.

Isolation of the human insulin-like growth factor I gene using a single synthetic DNA probe.

Ullrich A, Berman CH, Dull TJ, Gray A, Lee JM.

EMBO J. 1984 Feb;3(2):361-4.

46.

Human beta-nerve growth factor gene sequence highly homologous to that of mouse.

Ullrich A, Gray A, Berman C, Dull TJ.

Nature. 1983 Jun 30;303(5920):821-5.

PMID:
6688123
47.
48.

Sequence homology of human and mouse beta-NGF subunit genes.

Ullrich A, Gray A, Berman C, Coussens L, Dull TJ.

Cold Spring Harb Symp Quant Biol. 1983;48 Pt 1:435-42. No abstract available.

PMID:
6327169
49.

Nucleotide sequence of a portion of human chromosome 9 containing a leukocyte interferon gene cluster.

Ullrich A, Gray A, Goeddel DV, Dull TJ.

J Mol Biol. 1982 Apr 15;156(3):467-86. No abstract available.

PMID:
6181262
50.

Variation in the sequence and modification state of the human insulin gene flanking regions.

Ullrich A, Dull TJ, Gray A, Philips JA 3rd, Peter S.

Nucleic Acids Res. 1982 Apr 10;10(7):2225-40.

Supplemental Content

Support Center